Bancroft Fund Ltd. (AMEX:BCV) released on Monday November 22, 2010 unaudited monthly portfolio data for October including asset allocation, quality allocation, representative holdings and other fund characteristics. The portfolio data will be posted on Bancroft's website at www.bancroftfund.com.
Bancroft Fund Ltd. (the Fund) is a diversified, closed-end management investment company. The Fund invests primarily in convertible securities with the objectives of providing income and the potential for capital appreciation.
Power3 Medical Announces Execution of Definitive Agreement to Acquire Rozetta-Cell Life Sciences
Power3 Medical Products, Inc. (OTC:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced recently that it has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc.
Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger.
The acquisition of Rozetta-Cell is expected to be completed by end of Dec 2010.
Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally.
Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.
To learn more about PWRM visit: http://www.Power3Medical.com
Eaton Vance Limited Duration Income Fund (AMEX:EVV) announced the Board of Trustees of Eaton Vance Limited Duration Income Fund (the "Fund") a closed-end investment company, voted to hold the Annual Meeting of Shareholders of the Fund on Friday, February 25, 2011 at 2:30 p.m. (EST).
Eaton Vance Limited Duration Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund’s primary investment objective is to provide current income.
MusclePharm(NYSE:R) Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, has been invited to present at the upcoming HIV DART(NYSE:TM) 2010: Frontiers in Drug development for Antiretroviral Therapies Conference being held from December 7-10, 2010 in Los Cabos, Mexico.
This innovative conference, HIV DART(TM) 2010, will uniquely blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community an increased understanding of the current and future challenges in therapeutics for HIV infection. This brings leaders in the research community together to advance the medical communities knowledge of the ongoing drug development processes in antiretroviral research.
At this year's HIV DART(TM) 2010 Conference, MusclePharm will present its results on the use of its product, Recon, in HIV patients. Early results show that Recon may help prevent the onset of wasting syndrome by facilitating the growth and maintenance of muscle mass in people living with HIV, which has been associated with antiretroviral drug resistance.
MusclePharm has recently expanded their market to include therapeutic medical modalities beginning with the utilization of Recon, a multi-component therapeutic nutritional supplement in the treatment of people living with HIV and AIDS.
Nuveen Missouri Premium Income Municipal Fund (AMEX:NOM) announced on Wednesday November 24, 2010 that the Nuveen Ohio Dividend Advantage Municipal Fund called for redemption at par a portion of its outstanding auction-rate preferred securities (ARPS).
The fund’s Board of Trustees had previously approved this redemption, which totals more than $16 million. This redemption will be funded by proceeds received from the issuance of MuniFund Term Preferred Shares (NYSE:MTP).
Nuveen Investments provides high quality investment services designed to help secure the long-term goals of institutions and high net worth investors as well as the consultants and financial advisors who serve them.
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM). Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (OTCQB:MSLP).